CLINICAL_TRIALS
trial_result
· 2011-05-04
Clinical Trial Update: Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration [Phase 2]
Summary
Pfizer-sponsored Phase 2 trial of pegaptanib sodium (Macugen) for wet age-related macular degeneration has completed, with results posted in 2011.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2011-05-04